Novavax's COVID-19 Vaccine Shows Promising Results in SHIELD-Utah Study

In an exciting development for vaccine technology, Novavax, Inc. (Nasdaq: NVAX) announced the preliminary results of its SHIELD-Utah study on April 15, 2025. The study, which focused on healthcare workers and first responders, revealed that Novavax's COVID-19 vaccine, specifically the 2024-2025 formula targeting the JN.1 strain, induces lower reactogenicity symptoms compared to the Pfizer-BioNTech mRNA vaccine. This revelation adds a significant dimension to the ongoing discussion about vaccine options available to the public.

The SHIELD-Utah study, which took place between September and December 2024 in collaboration with the University of Utah Health, provided compelling insights into vaccine tolerability.

The study found that recipients of the Novavax vaccine reported significantly fewer and less severe reactogenicity symptoms than those who received the Pfizer-BioNTech vaccine. On average, Novavax recipients experienced 1.7 systemic symptoms compared to 2.8 in Pfizer-BioNTech recipients. Notably, 43.8% of Pfizer-BioNTech recipients reported at least one symptom of Grade 2 or higher, while only 24.2% of Novavax recipients experienced similar symptoms.

Moreover, the study highlighted the impact of these symptoms on daily activities. Novavax recipients reported fewer hours of reduced activity, averaging 0.7 hours for missed work and 0.8 hours for decreased productivity. In contrast, Pfizer-BioNTech recipients averaged 1.4 hours and 2.4 hours, respectively. This indicates that Novavax's vaccine not only mitigates symptoms but also supports better functional outcomes for recipients.

Dr. Sarang K. Yoon, Principal Investigator at the University of Utah Health, emphasized the importance of these findings. "The risk of side effects or reactogenicity has been shown to be a major decision factor for those opting to get vaccinated," he stated. The data from the SHIELD-Utah study contributes valuable insights to the public debate surrounding COVID-19 vaccination choices.

Ruxandra Draghia-Akli, Executive Vice President and Head of Research and Development at Novavax, expressed optimism about the study's implications for the company's broader research agenda. "Today's results add to an increasing body of research underscoring the tolerability of Novavax's COVID-19 vaccine," she noted. The company continues to focus on leveraging its innovative protein-based nanoparticles and Matrix-M® adjuvant technology to enhance vaccine performance.

The SHIELD-Utah study was a prospective, interventional trial (NCT06633835) involving a total of 588 healthcare workers, including physicians, nurses, and medical assistants. Participants had the option to choose between the Novavax and Pfizer-BioNTech vaccines and were asked to complete a post-vaccination questionnaire assessing reactogenicity symptoms and their impact on daily activities.

The findings from the SHIELD-Utah study are a significant step forward for Novavax as it continues to navigate the competitive landscape of COVID-19 vaccinations. With compelling evidence of lower reactogenicity symptoms and a favorable impact on daily life, Novavax's 2024-2025 vaccine formula may offer a valuable alternative for individuals seeking vaccination options. The company remains committed to advancing its research and development pipeline, with an eye towards future innovations built on its powerful technology platform.